Takeda Pharmaceutical (NYSE:TAK) Stock Rating Lowered by Zacks Investment Research

Wednesday, September 15, 2021 | MarketBeat

Takeda Pharmaceutical (NYSE:TAK) was downgraded by Zacks Investment Research from a "strong-buy" rating to a "hold" rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, "Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan. "

NYSE TAK opened at $16.75 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.03 and a current ratio of 1.51. The firm's 50 day moving average price is $16.76 and its 200-day moving average price is $17.19. Takeda Pharmaceutical has a 52-week low of $15.30 and a 52-week high of $19.97. The company has a market cap of $53.01 billion, a PE ratio of 11.47 and a beta of 1.05.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Friday, July 30th. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $8.68 billion for the quarter. Takeda Pharmaceutical had a net margin of 14.69% and a return on equity of 13.00%. On average, analysts forecast that Takeda Pharmaceutical will post 2.18 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in TAK. Russell Investments Group Ltd. purchased a new position in shares of Takeda Pharmaceutical in the second quarter worth $3,671,000. Catalyst Capital Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 27.2% in the first quarter. Catalyst Capital Advisors LLC now owns 112,300 shares of the company's stock worth $2,051,000 after buying an additional 24,000 shares during the last quarter. Glenview Capital Management LLC raised its holdings in shares of Takeda Pharmaceutical by 5.5% in the first quarter. Glenview Capital Management LLC now owns 16,104,222 shares of the company's stock worth $294,063,000 after buying an additional 843,710 shares during the last quarter. HRT Financial LP purchased a new position in shares of Takeda Pharmaceutical in the first quarter worth $1,439,000. Finally, O Shaughnessy Asset Management LLC raised its holdings in shares of Takeda Pharmaceutical by 42.7% in the first quarter. O Shaughnessy Asset Management LLC now owns 32,923 shares of the company's stock worth $601,000 after buying an additional 9,852 shares during the last quarter. Institutional investors own 2.99% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Co, Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products.

Further Reading: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Takeda Pharmaceutical right now?

Before you consider Takeda Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.

While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.